Biofrontera reports Q4 2022 rev $10.1M (+11% YoY); FY rev $28.7M (+19%); guides 25% growth in 2023

Biofrontera Inc.

Total revenue Q4 2022 $10.1M (+11% YoY); FY 2022 $28.7M (+19% YoY).
Net loss Q4 $2.8M vs $14.5M in Q4 2021; FY net loss $0.64M vs $37.7M in 2021.
Adjusted EBITDA negative $4.4M in Q4 and negative $18.1M for FY 2022.
Guidance: FY 2023 revenue growth at least 25%; expects cash flow positive within ~2 years.
Expanding salesforce to 50-55 over next couple of years; will stop providing preliminary quarterly revenue.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $10.1 million, net income $2.8 million. Guidance raised.

Period: fourth quarter and fiscal year ended December 31, 2022
Revenue: $10.1 million
Net income: $2.8 million
Guidance: raised
Result: reported results

Exact text from the filing

at least 25% over last year positioning us well to be cashflow positive within approximately two years.” Fourth Quarter Financial Results Fourth quarter 2022 total revenues of $10.1 million, compared with $9.2 million in the fourth quarter of 2021. The increase was driven by continued growth in the sales of Ameluz, partially offset by shipping delays and some sales

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-007001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.